Bacteriophages are viruses that specifically target and kill bacteria, preventing bacterial infections, and Dr. Andrew Camilli and his lab study the bacteriophages that kill V. cholerae. Dr. Camilli is also co-founder and scientific advisor to PhagePro, Inc., a Boston-based startup aiming to use bacteriophages to prevent bacterial infections. With the unmitigated rise of antibiotic resistance and the known negative consequences of gut dysbiosis caused by broad-spectrum antibiotics, bacteriophages provide a side effect-free alternative for preventing disease in clinical and community contexts.
From Detection to Predicting Infectious Disease and Antibiotic Resistance Outcomes: Employing Experimental Evolution, Omics-Stress Mapping and Computational Biology to Determine and Predict What Matters in Antibiotic Resistance
Tim van Opijnen, PhD, an Associate Professor of Biology at Boston College and an Affiliate member of the Levy CIMAR, presented for our May 2021 Levy CIMAR Science Lunch on his group's work on antimicrobial resistance. His talk was titled, "From Detection to Predicting Infectious Disease and Antibiotic Resistance Outcomes: Employing Experimental Evolution, Omics-Stress Mapping and Computational Biology to Determine and Predict What Matters in Antibiotic Resistance." Dr. Martinot is an Assistant Professor in the Department of Infectious Diseases and Global Health at Cummings. She is a board-certified veterinary pathologist
Veterinary pathologist Amanda J. Martinot (DVM, MPH, PhD) of the Tufts University Cummings School of Veterinary Medicine presented for our Monthly Science Meeting on Thursday, January 28, on two articles of interest in the COVID-19 pandemic: The first on the pre-clinical results for the Regeneron monoclonal Ab for SARS CoV-2 in hamsters and monkeys (Science), with additional discussion of the clinical trial of the same in people (NEJM). You can find a video of her talk below. Dr. Martinot is an Assistant Professor in the Department of Infectious Diseases and Global
Trials and Tribulations of Antimicrobial Drug Development: Assessing the Economic and Political Landscape
As an internationally recognized expert on drug development science and policy, the Levy CIMAR's Dr. Kenneth I. Kaitin writes and speaks regularly on factors that contribute to the slow pace and high cost of pharmaceutical R&D and efforts to improve the development process. He has provided public testimony before the U.S. Congress on pharmaceutical development, regulation, and policy issues, and he currently serves as an expert consultant to the U.S. Department of Defense on bioterror countermeasures initiatives.During his 23 years as Tufts CSDD's Director, the group has tackled complex and
The Levy CIMAR hosted our second annual collaborative workshop titled “Fighting AMR Together” earlier this month, offering a platform for investigators and clinicians to showcase their research and promoting opportunities for partnership both within and outside of the Tufts network. The two-day workshop, held Nov. 5-6, 2020, began with welcoming remarks from Levy CIMAR Director Helen Boucher, MD, Senior Leadership member, John Leong, MD/PhD, and Executive Director Brian Noonan, PhD, on the Center’s achievements so far and our plans for the near future.
We at the Levy CIMAR are honored to be named for Dr. Stuart B. Levy, whose pioneering work in fighting antibiotic misuse and resistance was a key inspiration behind our Center. During his more than four decades at Tufts University and Tufts Medical Center, Dr. Levy led the paradigm shift in how we view antibiotic use and stewardship. In his work on mechanisms of antibiotic resistance and spread of resistance determinants among microbes, his was the first voice of warning of the dangers of antibiotic overuse in the emergence of
Tufts Mini-Med School dovetails with CIMAR’s mission in that it is uniquely interdisciplinary in its One Health approach. The program draws on an array of schools beyond the School of Medicine dedicated to the health science and medicine at Tufts University, including: the School of Dental Medicine, the Cummings School of Veterinary Medicine, the Friedman School of Nutrition Science & Policy, and the Graduate School of Biomedical Sciences. The program emphasized infectious diseases and immunology, with examples drawn from the COVID-19 pandemic. The students also learned about multi-drug resistance/antimicrobial resistance
CIMAR hosted 33 students from Boston-area Brockton High School last week for a rare educational and networking opportunity. Students presented posters depicting original experiments and data on antimicrobial resistance to a wide audience of Tufts University and Tufts Medical Center members.
Breaking the Chain of Infection: Tufts@Kendall Event Connects Tufts Researchers and the Biomedical Industry
Tufts and MassBio held the first Tufts@Kendall event, bringing together CIMAR researchers and clinicians with more than 80 members of the biomedical community to discuss the latest advances in infectious disease and antimicrobial resistance at Tufts University.
Drug-Resistant Superbugs: CIMAR Symposium Examines the Intersection of People, Animals, Food, and the Environment, and Their Impact on Health
The event brought together over 175 clinicians and researchers from academia, medicine, and industry, all interested in fighting drug-resistant diseases via a “One Health” approach. One Health prioritizes the relationship among people, animals, the environment, and the foods we all consume as critical avenues by which drug-resistant bacteria spread from one to another
The Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR) hosted its first event last month to introduce the Center to the local scientific community and to offer a platform for investigators and clinicians to showcase their research and promote collaborations.